Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.

GLP-1 metabolite GLP-1(9–36) is a systemic inhibitor of mouse and human pancreatic islet glucagon secretion

Open access

Abstract

Aims/hypothesis: Diabetes mellitus is associated with impaired insulin secretion, often aggravated by oversecretion of glucagon. Therapeutic interventions should ideally correct both defects. Glucagon-like peptide 1 (GLP-1) has this capability but exactly how it exerts its glucagonostatic effect remains obscure. Following its release GLP-1 is rapidly degraded from GLP-1(7–36) to GLP-1(9–36). We hypothesised that the metabolite GLP-1(9–36) (previously believed to be biologically inactive) exerts a direct inhibitory effect on glucagon secretion and that this mechanism becomes impaired in diabetes. Methods: We used a combination of glucagon secretion measurements in mouse and human islets (including islets from donors with type 2 diabetes), total internal reflection fluorescence microscopy imaging of secretory granule dynamics, recordings of cytoplasmic Ca 2+ and measurements of protein kinase A activity, immunocytochemistry, in vivo physiology and GTP-binding protein dissociation studies to explore how GLP-1 exerts its inhibitory effect on glucagon secretion and the role of the metabolite GLP-1(9–36). Results: GLP-1(7–36) inhibited glucagon secretion in isolated islets with an IC 50 of 2.5 pmol/l. The effect was particularly strong at low glucose concentrations. The degradation product GLP-1(9–36) shared this capacity. GLP-1(9–36) retained its glucagonostatic effects after genetic/pharmacological inactivation of the GLP-1 receptor. GLP-1(9–36) also potently inhibited glucagon secretion evoked by β-adrenergic stimulation, amino acids and membrane depolarisation. In islet alpha cells, GLP-1(9–36) led to inhibition of Ca 2+ entry via voltage-gated Ca 2+ channels sensitive to ω-agatoxin, with consequential pertussis-toxin-sensitive depletion of the docked pool of secretory granules, effects that were prevented by the glucagon receptor antagonists REMD2.59 and L-168049. The capacity of GLP-1(9–36) to inhibit glucagon secretion and reduce the number of docked granules was lost in alpha cells from human donors with type 2 diabetes. In vivo, high exogenous concentrations of GLP-1(9–36) (>100 pmol/l) resulted in a small (30%) lowering of circulating glucagon during insulin-induced hypoglycaemia. This effect was abolished by REMD2.59, which promptly increased circulating glucagon by >225% (adjusted for the change in plasma glucose) without affecting pancreatic glucagon content. Conclusions/interpretation: We conclude that the GLP-1 metabolite GLP-1(9–36) is a systemic inhibitor of glucagon secretion. We propose that the increase in circulating glucagon observed following genetic/pharmacological inactivation of glucagon signalling in mice and in people with type 2 diabetes reflects the removal of GLP-1(9–36)’s glucagonostatic action. Graphical Abstract:

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00125-023-06060-w

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 GLP-1 inhibits glucagon secretion. (a) Effect of increasing concentrations of GLP-1(7–36) on glucagon secretion in isolated mouse islets. Each data point represents a unique group of 12 islets isolated from 4–6 mice. Glucagon secretion has been normalised to that at 1 mmol/l glucose (1=17±0.36 pg islet−1 h−1). Rectangles and error bars represent mean values ± SEM. ***p<0.001 (one-way ANOVA followed by Tukey’s post hoc test). (b) As for (a) but using GLP-1(9–36) (1=10.0±0.4 pg islet−1 h−1). ***p<0.001. (c, d) As for (a, b) but effects on somatostatin secretion were measured. Each data point represents a unique group of 20 islets isolated from 4 mice. Somatostatin secretion has been normalised to that at 1 mmol/l glucose (1=0.074±0.007% and 0.055±0.004% of content/h in c and d, respectively). **p<0.01, ***p<0.001 (one-way ANOVA followed by Tukey’s post hoc test). (e, f) As for (c, d) but insulin secretion was measured (1=0.055±0.003% and 0.065±0.003% of content/h in e and f, respectively). **p<0.01, ***p<0.001 (one-way ANOVA followed by Tukey’s post hoc test). (g) Effects of GLP-1(9-36) and GLP-1(7-36) on insulin secretion at 1 and 10 mmol/l glucose. Insulin secretion has been normalised to that at 1 mmol/l glucose (1=29±2 pg islet−1 h−1). ***p<0.001 vs 1 mmol/l glucose; †††p<0.001 vs 10 mmol/l glucose and 30 pmol/l GLP-1(9–36) (one-way ANOVA followed by Tukey’s post hoc test). Concentrations of GLP-1(9–36) and GLP-1(7–36) used at both the glucose concentrations. (h) As for (g) but glucagon secretion was measured (1=4.2±0.3 pg islet−1 h−1). ***p<0.001 vs 1 mmol/l glucose; †††p<0.001 vs 10 mmol/l glucose alone; ‡p<0.05 vs 1 mmol/l glucose and 30 pmol/l GLP-1(9–36) (one-way ANOVA followed by Tukey’s post hoc test)
Fig. 1 GLP-1 inhibits glucagon secretion. (a) Effect of increasing concentrations of GLP-1(7–36) on glucagon secretion in isolated mouse islets. Each data point represents a unique group of 12 islets isolated from 4–6 mice. Glucagon secretion has been normalised to that at 1 mmol/l glucose (1=17±0.36 pg islet−1 h−1). Rectangles and error bars represent mean values ± SEM. ***p<0.001 (one-way ANOVA followed by Tukey’s post hoc test). (b) As for (a) but using GLP-1(9–36) (1=10.0±0.4 pg islet−1 h−1). ***p<0.001. (c, d) As for (a, b) but effects on somatostatin secretion were measured. Each data point represents a unique group of 20 islets isolated from 4 mice. Somatostatin secretion has been normalised to that at 1 mmol/l glucose (1=0.074±0.007% and 0.055±0.004% of content/h in c and d, respectively). **p<0.01, ***p<0.001 (one-way ANOVA followed by Tukey’s post hoc test). (e, f) As for (c, d) but insulin secretion was measured (1=0.055±0.003% and 0.065±0.003% of content/h in e and f, respectively). **p<0.01, ***p<0.001 (one-way ANOVA followed by Tukey’s post hoc test). (g) Effects of GLP-1(9-36) and GLP-1(7-36) on insulin secretion at 1 and 10 mmol/l glucose. Insulin secretion has been normalised to that at 1 mmol/l glucose (1=29±2 pg islet−1 h−1). ***p<0.001 vs 1 mmol/l glucose; †††p<0.001 vs 10 mmol/l glucose and 30 pmol/l GLP-1(9–36) (one-way ANOVA followed by Tukey’s post hoc test). Concentrations of GLP-1(9–36) and GLP-1(7–36) used at both the glucose concentrations. (h) As for (g) but glucagon secretion was measured (1=4.2±0.3 pg islet−1 h−1). ***p<0.001 vs 1 mmol/l glucose; †††p<0.001 vs 10 mmol/l glucose alone; ‡p<0.05 vs 1 mmol/l glucose and 30 pmol/l GLP-1(9–36) (one-way ANOVA followed by Tukey’s post hoc test)CC BY · PubMed Central
Fig. 2 GLP-1’s glucagonostatic effect does not require Glp1r. (a) Effects of 10 pmol/l GLP-1(7–36) on glucagon secretion in wild-type (black) and Glp1r−/− (grey) islets. Each data point represents a unique group of 12 islets isolated from 4 mice of each genotype. Glucagon secretion has been normalised to that at 1 mmol/l glucose (1=3.4±0.46 pg islet−1 h−1 and 2.6±0.2 pg islet−1 h−1 in wild-type and Glp1r−/− islets, respectively). *p<0.05 vs control in wild-type islets; ††p<0.01 vs control in Glp1r−/− islets. (b) As for (a) but testing 10 pmol/l GLP-1(9–36) and using 3 mice of each genotype (1=3.5±0.5 pg islet−1 h−1 and 2.2±0.17 pg islet−1 h−1 in wild-type and Glp1r−/− islets, respectively). **p<0.05 vs control in wild-type islets; †p<0.05 vs control in Glp1r−/− islets. (c) Effects of 10 pmol/l GLP-1(7–36) and (9–36) on glucagon secretion in the absence and presence of the GLP-1R antagonist exendin(9–39) (1 μmol/l) as indicated. Each data point represents a unique group of 12 islets isolated from 8 mice. Glucagon secretion has been normalised to that at 1 mmol/l glucose (1=7.4±0.2 pg islet−1 h−1). ***p<0.001 vs 1 mmol/l glucose; †††p<0.001 vs exendin(9–39); ‡‡‡p<0.001 vs 10 pmol/l GLP-1(9–36). (d) Effects of exendin-4 (10 pmol/l) in the absence and presence of exendin(9–39) (1 μmol/l) as indicated. Each data point represents a unique group of 12 islets isolated from 8 mice. Glucagon secretion has been normalised to that at 1 mmol/l glucose (1=3.88±0.12 pg islet−1 h−1). ***p<0.001. Statistical analyses in (a–c) were carried out by one-way ANOVA followed by Tukey’s post hoc test
Fig. 2 GLP-1’s glucagonostatic effect does not require Glp1r. (a) Effects of 10 pmol/l GLP-1(7–36) on glucagon secretion in wild-type (black) and Glp1r−/− (grey) islets. Each data point represents a unique group of 12 islets isolated from 4 mice of each genotype. Glucagon secretion has been normalised to that at 1 mmol/l glucose (1=3.4±0.46 pg islet−1 h−1 and 2.6±0.2 pg islet−1 h−1 in wild-type and Glp1r−/− islets, respectively). *p<0.05 vs control in wild-type islets; ††p<0.01 vs control in Glp1r−/− islets. (b) As for (a) but testing 10 pmol/l GLP-1(9–36) and using 3 mice of each genotype (1=3.5±0.5 pg islet−1 h−1 and 2.2±0.17 pg islet−1 h−1 in wild-type and Glp1r−/− islets, respectively). **p<0.05 vs control in wild-type islets; †p<0.05 vs control in Glp1r−/− islets. (c) Effects of 10 pmol/l GLP-1(7–36) and (9–36) on glucagon secretion in the absence and presence of the GLP-1R antagonist exendin(9–39) (1 μmol/l) as indicated. Each data point represents a unique group of 12 islets isolated from 8 mice. Glucagon secretion has been normalised to that at 1 mmol/l glucose (1=7.4±0.2 pg islet−1 h−1). ***p<0.001 vs 1 mmol/l glucose; †††p<0.001 vs exendin(9–39); ‡‡‡p<0.001 vs 10 pmol/l GLP-1(9–36). (d) Effects of exendin-4 (10 pmol/l) in the absence and presence of exendin(9–39) (1 μmol/l) as indicated. Each data point represents a unique group of 12 islets isolated from 8 mice. Glucagon secretion has been normalised to that at 1 mmol/l glucose (1=3.88±0.12 pg islet−1 h−1). ***p<0.001. Statistical analyses in (a–c) were carried out by one-way ANOVA followed by Tukey’s post hoc testCC BY · PubMed Central
Fig. 3 GLP-1(9–36) exerts its glucagonostatic effects by PTX-sensitive mechanisms. (a, b) Effects of GLP-1(7–36) and GLP-1(9–36) on glucagon release without (a) or with (b) overnight pretreatment with PTX (100 ng/ml) as indicated. Each data point represents a unique group of 12 islets isolated from 16 mice. Glucagon secretion has been normalised to that at 1 mmol/l glucose (1=10.7±0. pg islet−1 h−1). ***p<0.001 vs control; †††p<0.001 vs 1 mmol/l glucose in PTX-treated islets. In (a) islets were cultured overnight without PTX. (c) Effects of 10 pmol/l GLP-1(7–36) on glucagon release in Glp1r−/− islets under control conditions and after pretreatment with PTX. Each data point represents a unique group of 12 islets isolated from 10 mice. Glucagon secretion has been normalised to that at 1 mmol/l glucose (1=4.3±0.6 pg islet−1 h−1 and 5.7±0.95 pg islet−1 h−1 in the absence and presence of PTX, respectively. *p<0.05 vs no GLP-1(7–36) in control islets. (d) Schematic showing conversion of GLP-1(7–36) into GLP-1(9–36) and impact of PTX pretreatment. GLP-1(7–36) (and exendin-4), via activation of GLP-1Rs in beta and delta cells, inhibits glucagon secretion by a PTX-resistant paracrine mechanism (rectangle) that is lost following ablation of the GLP-1R (Glp1r−/−). Statistical analyses in (a–c) were carried out by one-way ANOVA followed by Tukey’s post hoc test
Fig. 3 GLP-1(9–36) exerts its glucagonostatic effects by PTX-sensitive mechanisms. (a, b) Effects of GLP-1(7–36) and GLP-1(9–36) on glucagon release without (a) or with (b) overnight pretreatment with PTX (100 ng/ml) as indicated. Each data point represents a unique group of 12 islets isolated from 16 mice. Glucagon secretion has been normalised to that at 1 mmol/l glucose (1=10.7±0. pg islet−1 h−1). ***p<0.001 vs control; †††p<0.001 vs 1 mmol/l glucose in PTX-treated islets. In (a) islets were cultured overnight without PTX. (c) Effects of 10 pmol/l GLP-1(7–36) on glucagon release in Glp1r−/− islets under control conditions and after pretreatment with PTX. Each data point represents a unique group of 12 islets isolated from 10 mice. Glucagon secretion has been normalised to that at 1 mmol/l glucose (1=4.3±0.6 pg islet−1 h−1 and 5.7±0.95 pg islet−1 h−1 in the absence and presence of PTX, respectively. *p<0.05 vs no GLP-1(7–36) in control islets. (d) Schematic showing conversion of GLP-1(7–36) into GLP-1(9–36) and impact of PTX pretreatment. GLP-1(7–36) (and exendin-4), via activation of GLP-1Rs in beta and delta cells, inhibits glucagon secretion by a PTX-resistant paracrine mechanism (rectangle) that is lost following ablation of the GLP-1R (Glp1r−/−). Statistical analyses in (a–c) were carried out by one-way ANOVA followed by Tukey’s post hoc testCC BY · PubMed Central
Fig. 4 Glucagon receptors in alpha cells and their activation by GLP-1(9–36). (a) Glucagon receptor (GCGR) immunoreactivity in alpha cells. Double immunofluorescence staining of GCGR (green) and glucagon (red) in a mouse pancreatic islet. GCGR staining was merged with glucagon staining to test the co-localisation. GCGR and glucagon double-positive cells are indicated with white arrows. Scale bar, 10 μm. (b) Effects of increasing concentrations of glucagon or GLP-1(9–36) (logarithmic scale) on dissociation of the GoA GTP-binding protein α-subunit from GCGRs expressed in HEK293T cells using the TRUPATH biosensor platform. Effects are expressed as the ligand-induced change in BRET (relative to that in the absence of any peptides; ΔBRET, y-axis) against concentration of glucagon or GLP-1(9–36) (x-axis). Data representative of 4 and 3 replicates for glucagon and GLP-1(9–36), respectively. See also ESM Table 4.
Fig. 4 Glucagon receptors in alpha cells and their activation by GLP-1(9–36). (a) Glucagon receptor (GCGR) immunoreactivity in alpha cells. Double immunofluorescence staining of GCGR (green) and glucagon (red) in a mouse pancreatic islet. GCGR staining was merged with glucagon staining to test the co-localisation. GCGR and glucagon double-positive cells are indicated with white arrows. Scale bar, 10 μm. (b) Effects of increasing concentrations of glucagon or GLP-1(9–36) (logarithmic scale) on dissociation of the GoA GTP-binding protein α-subunit from GCGRs expressed in HEK293T cells using the TRUPATH biosensor platform. Effects are expressed as the ligand-induced change in BRET (relative to that in the absence of any peptides; ΔBRET, y-axis) against concentration of glucagon or GLP-1(9–36) (x-axis). Data representative of 4 and 3 replicates for glucagon and GLP-1(9–36), respectively. See also ESM Table 4.CC BY · PubMed Central
Fig. 5 GLP-1(9–36) inhibits PKA activity and glucagon secretion by GCGR-dependent mechanism. (a) Effects of increasing concentrations of GLP-1(9–36) (staircase) on PKA activity in individual alpha cells in intact islets under control conditions (n=420 cells from 3 mice) and after pretreatment with PTX (n=785 cells from 3 mice). Data are mean values ± SEM. (b) PKA activity in alpha cells in response to 10 and 100 pmol/l GLP-1(9–36) in the presence of 100 nmol/l of L-168049 (n=420 cells from 3 mice). In (a, b) responses have been normalised to basal conditions prior to the addition of the agonists. (c) Box plots of changes in PKA activity in response to 10 pmol/l GLP-1(9–36) under control conditions and after pretreatment with PTX (n=785 cells from 3 mice) or in the presence of 100 nmol/l of L-168049. **p<0.01 vs basal level (evaluated by Friedman ANOVA, Nemenyi post hoc test); †p<0.05 vs GLP-1(9–36) in the absence of L-168049 (Kruskal–Wallis ANOVA, Nemenyi’s post hoc test). Black lines represent medians and the boxes indicate first and third quartiles. (d) As for (b) but testing the effects of 10 pmol/l and 10,000 pmol/l GLP-1(7–36) (n=420 cells from 3 mice). (e) Effects of GLP-1(7–36) and (9–36) on glucagon secretion in the absence (black) or presence (red) of 8-Br-Rp-cAMPS (10 μmol/l) as indicated. Each data point represents a unique group of 12 islets isolated from 10–11 mice. Glucagon secretion has been normalised to that at 1 mmol/l glucose (1=1.8±0.3 pg islet−1 h−1). ***p<0.001 vs control in the absence of 8-Br-Rp-cAMPS; ††p<0.01 and †††p<0.001 vs control in the presence of 8-Br-Rp-cAMPS (one-way ANOVA and Tukey’s post hoc test). (f) Effects of 10 pmol/l and 1000 pmol/l GLP-1(9–36) on glucagon secretion in the absence (black) or presence (red) of 100 nmol/l of the monoclonal antibody/antagonist REMD2.59. Each data point represents a unique group of 12 islets isolated from 6 mice. Glucagon secretion has been normalised to that at 1 mmol/l glucose (1=7.4±0.1 pg islet−1 h−1). ***p<0.001 vs no GLP-1(9–36); †††p<0.001 vs 10 pmol/l GLP-1 in the absence of REMD2.59 (one-way ANOVA followed by Tukey’s post hoc test)
Fig. 5 GLP-1(9–36) inhibits PKA activity and glucagon secretion by GCGR-dependent mechanism. (a) Effects of increasing concentrations of GLP-1(9–36) (staircase) on PKA activity in individual alpha cells in intact islets under control conditions (n=420 cells from 3 mice) and after pretreatment with PTX (n=785 cells from 3 mice). Data are mean values ± SEM. (b) PKA activity in alpha cells in response to 10 and 100 pmol/l GLP-1(9–36) in the presence of 100 nmol/l of L-168049 (n=420 cells from 3 mice). In (a, b) responses have been normalised to basal conditions prior to the addition of the agonists. (c) Box plots of changes in PKA activity in response to 10 pmol/l GLP-1(9–36) under control conditions and after pretreatment with PTX (n=785 cells from 3 mice) or in the presence of 100 nmol/l of L-168049. **p<0.01 vs basal level (evaluated by Friedman ANOVA, Nemenyi post hoc test); †p<0.05 vs GLP-1(9–36) in the absence of L-168049 (Kruskal–Wallis ANOVA, Nemenyi’s post hoc test). Black lines represent medians and the boxes indicate first and third quartiles. (d) As for (b) but testing the effects of 10 pmol/l and 10,000 pmol/l GLP-1(7–36) (n=420 cells from 3 mice). (e) Effects of GLP-1(7–36) and (9–36) on glucagon secretion in the absence (black) or presence (red) of 8-Br-Rp-cAMPS (10 μmol/l) as indicated. Each data point represents a unique group of 12 islets isolated from 10–11 mice. Glucagon secretion has been normalised to that at 1 mmol/l glucose (1=1.8±0.3 pg islet−1 h−1). ***p<0.001 vs control in the absence of 8-Br-Rp-cAMPS; ††p<0.01 and †††p<0.001 vs control in the presence of 8-Br-Rp-cAMPS (one-way ANOVA and Tukey’s post hoc test). (f) Effects of 10 pmol/l and 1000 pmol/l GLP-1(9–36) on glucagon secretion in the absence (black) or presence (red) of 100 nmol/l of the monoclonal antibody/antagonist REMD2.59. Each data point represents a unique group of 12 islets isolated from 6 mice. Glucagon secretion has been normalised to that at 1 mmol/l glucose (1=7.4±0.1 pg islet−1 h−1). ***p<0.001 vs no GLP-1(9–36); †††p<0.001 vs 10 pmol/l GLP-1 in the absence of REMD2.59 (one-way ANOVA followed by Tukey’s post hoc test)CC BY · PubMed Central
Fig. 6 GLP-1(9–36) inhibits both depolarisation- and agonist-induced glucagon secretion. (a) Glucagon secretion at 3.6 or 70 mmol/l extracellular K+ ([K+]o) in the absence or presence of GLP-1(9–36) as indicated. Each data point represents a unique group of 12 islets isolated from 6 mice). Glucagon secretion has been normalised to that at 1 mmol/l glucose (1=16.9±1.9 pg islet−1 h−1). ***p<0.001 vs 1 mmol/l glucose at 3.6 mmol/l [K+]o; †††p<0.001 vs 70 mmol/l [K+]o alone. (b) Glucagon secretion at 1 mmol/l glucose in the absence or presence of a cocktail of AAs (2 mmol/l each of glutamine, alanine and arginine) and GLP-1(9–36) as indicated. Each data point represents a unique group of 12 islets isolated from 10 mice. Glucagon secretion has been normalised to that at 1 mmol/l glucose (1=36.5±7.3 pg islet−1 h−1). ***p<0.001vs no AAs; †p<0.05 vs 6 mmol/l AA alone. (c) As for (b) but testing the effects of isoprenaline (1=11±1.9 pg islet−1 h−1; 9 mice). ***p<0.001 vs 1 mmol/l glucose; †††p<0.001 vs isoprenaline. Statistical significance in (a–c) was estimated using one-way ANOVA with Tukey’s post hoc test
Fig. 6 GLP-1(9–36) inhibits both depolarisation- and agonist-induced glucagon secretion. (a) Glucagon secretion at 3.6 or 70 mmol/l extracellular K+ ([K+]o) in the absence or presence of GLP-1(9–36) as indicated. Each data point represents a unique group of 12 islets isolated from 6 mice). Glucagon secretion has been normalised to that at 1 mmol/l glucose (1=16.9±1.9 pg islet−1 h−1). ***p<0.001 vs 1 mmol/l glucose at 3.6 mmol/l [K+]o; †††p<0.001 vs 70 mmol/l [K+]o alone. (b) Glucagon secretion at 1 mmol/l glucose in the absence or presence of a cocktail of AAs (2 mmol/l each of glutamine, alanine and arginine) and GLP-1(9–36) as indicated. Each data point represents a unique group of 12 islets isolated from 10 mice. Glucagon secretion has been normalised to that at 1 mmol/l glucose (1=36.5±7.3 pg islet−1 h−1). ***p<0.001vs no AAs; †p<0.05 vs 6 mmol/l AA alone. (c) As for (b) but testing the effects of isoprenaline (1=11±1.9 pg islet−1 h−1; 9 mice). ***p<0.001 vs 1 mmol/l glucose; †††p<0.001 vs isoprenaline. Statistical significance in (a–c) was estimated using one-way ANOVA with Tukey’s post hoc testCC BY · PubMed Central
Fig. 7 GLP-1 leads to undocking of secretory granules in alpha cells. (a) Docked granule density measured in mouse alpha cells in the absence (black) or presence (red) of GLP-1(9–36) (10 pmol/l). When tested, GLP-1(9–36) was included in the superfusion medium as indicated by the horizontal line. Data are mean values ± SEM of 7 cells from 3 mice for control and 12 cells from 4 mice for GLP-1(9–36). (b–d) Number of granules arriving (b), docking (c) and undocking (d) in the absence or presence of GLP-1(9–36) during 15 min in the experiments summarised in (a). Data in bar graphs represent mean values ± SEM superimposed on individual data points. (e–h) Granule density measured in the absence or presence of GLP-1(9–36) under control conditions (e), in the presence of exendin(9–39) (100 nmol/l) (f), with the GCGR antagonist L-168049 (100 nmol/l) (g) and after pretreatment with PTX (100 ng/ml) for 16 h (h). Granule density was measured 15 min after addition of GLP-1(9–36). Data points correspond to individual cells obtained from at least 3 different mice. Cells were pretreated with exendin(9–39) and L-168049 for 15 min before measurements commenced. Data were normalised to membrane area. **p<0.01, ***p<0.001 vs no GLP-1(9–36) in each panel (Student’s t test)
Fig. 7 GLP-1 leads to undocking of secretory granules in alpha cells. (a) Docked granule density measured in mouse alpha cells in the absence (black) or presence (red) of GLP-1(9–36) (10 pmol/l). When tested, GLP-1(9–36) was included in the superfusion medium as indicated by the horizontal line. Data are mean values ± SEM of 7 cells from 3 mice for control and 12 cells from 4 mice for GLP-1(9–36). (b–d) Number of granules arriving (b), docking (c) and undocking (d) in the absence or presence of GLP-1(9–36) during 15 min in the experiments summarised in (a). Data in bar graphs represent mean values ± SEM superimposed on individual data points. (e–h) Granule density measured in the absence or presence of GLP-1(9–36) under control conditions (e), in the presence of exendin(9–39) (100 nmol/l) (f), with the GCGR antagonist L-168049 (100 nmol/l) (g) and after pretreatment with PTX (100 ng/ml) for 16 h (h). Granule density was measured 15 min after addition of GLP-1(9–36). Data points correspond to individual cells obtained from at least 3 different mice. Cells were pretreated with exendin(9–39) and L-168049 for 15 min before measurements commenced. Data were normalised to membrane area. **p<0.01, ***p<0.001 vs no GLP-1(9–36) in each panel (Student’s t test)CC BY · PubMed Central
Fig. 8 Impact of P/Q-type Ca2+ channel inhibition and type 2 diabetes on GLP-1(9–36)-induced granule undocking. (a) Glucagon secretion measured at 1 mmol/l glucose in the absence and presence of 10 pmol/l GLP-1(9–36) under control conditions (without ω-agatoxin) and in the presence of ω-agatoxin (200 nmol/l) as indicated. Note that the blocker, when added as indicated, was present in both the absence and presence of GLP-1(9–36). Each data point represents a unique group of 12 islets isolated from 6 mice. Glucagon secretion has been normalised to that at 1 mmol/l glucose (1=6.0±0.2 pg islet−1 h−1). **p<0.01 vs 1 mmol/l glucose; †p<0.05 vs 1 mmol/l glucose and ω-agatoxin (one-way ANOVA followed by Dunnet’s post hoc test). (b) Depolarisation-evoked increases in [Ca2+]i elicited by increasing extracellular K+ ([K+]o) from 3.6 to 70 mmol/l in the presence of 10 μmol/l isradipine (to block L-type Ca2+ channels). Under these experimental conditions depolarisation-induced Ca2+ entry will reflect P/Q-type Ca2+ channel activity. GLP-1(9–36) (10 pmol/l) and ω-agatoxin were included in the medium as indicated (n=139 cells from 4 mice). (c) Granule density measured in the absence or presence of ω-agatoxin (200 nmol/l). *p<0.05. (d) Effects of GLP-1(9–36) in the presence of ω-agatoxin (200 nmol/l). (e) As for (c) but testing the effect of diazoxide (0.2 mmol/l). Control cells were incubated in the presence of 0.1% DMSO (solvent used for diazoxide). ***p<0.001 vs 1 mmol/l glucose (Student’s t test). (f) Granule density measured in human alpha cells in the absence or presence of 10 pmol/l GLP-1(9–36) (measured after 15 min). Mean values ± SEM of 28 GLP-1(9–36)-treated and 27 control alpha cells from 3 donors. ***p<0.001 vs control (Student’s t test). (g) As for (f) but in alpha cells from donors with type 2 diabetes. Mean values ± SEM of 43 GLP-1(9–36)-treated and 31 control cells from two donors. ***p<0.001 vs control. (h) Effects of GLP-1(9–36) on glucagon secretion in islets from cadaveric healthy donors. Each data point represents a unique group of 12 islets isolated from 13 healthy donors (black bars and grey symbols) and 3 donors with type 2 diabetes (red bars and symbols). Glucagon secretion has been normalised to that at 1 mmol/l glucose (1=7.01±0.91 and 2.41±0.62 pg islet−1 h−1 from experiments carried out on islets from donors without and with type 2 diabetes, respectively). ***p<0.001 vs no GLP-1(9–36) in islets from healthy donors (one-way ANOVA with Dunnett’s post hoc test)
Fig. 8 Impact of P/Q-type Ca2+ channel inhibition and type 2 diabetes on GLP-1(9–36)-induced granule undocking. (a) Glucagon secretion measured at 1 mmol/l glucose in the absence and presence of 10 pmol/l GLP-1(9–36) under control conditions (without ω-agatoxin) and in the presence of ω-agatoxin (200 nmol/l) as indicated. Note that the blocker, when added as indicated, was present in both the absence and presence of GLP-1(9–36). Each data point represents a unique group of 12 islets isolated from 6 mice. Glucagon secretion has been normalised to that at 1 mmol/l glucose (1=6.0±0.2 pg islet−1 h−1). **p<0.01 vs 1 mmol/l glucose; †p<0.05 vs 1 mmol/l glucose and ω-agatoxin (one-way ANOVA followed by Dunnet’s post hoc test). (b) Depolarisation-evoked increases in [Ca2+]i elicited by increasing extracellular K+ ([K+]o) from 3.6 to 70 mmol/l in the presence of 10 μmol/l isradipine (to block L-type Ca2+ channels). Under these experimental conditions depolarisation-induced Ca2+ entry will reflect P/Q-type Ca2+ channel activity. GLP-1(9–36) (10 pmol/l) and ω-agatoxin were included in the medium as indicated (n=139 cells from 4 mice). (c) Granule density measured in the absence or presence of ω-agatoxin (200 nmol/l). *p<0.05. (d) Effects of GLP-1(9–36) in the presence of ω-agatoxin (200 nmol/l). (e) As for (c) but testing the effect of diazoxide (0.2 mmol/l). Control cells were incubated in the presence of 0.1% DMSO (solvent used for diazoxide). ***p<0.001 vs 1 mmol/l glucose (Student’s t test). (f) Granule density measured in human alpha cells in the absence or presence of 10 pmol/l GLP-1(9–36) (measured after 15 min). Mean values ± SEM of 28 GLP-1(9–36)-treated and 27 control alpha cells from 3 donors. ***p<0.001 vs control (Student’s t test). (g) As for (f) but in alpha cells from donors with type 2 diabetes. Mean values ± SEM of 43 GLP-1(9–36)-treated and 31 control cells from two donors. ***p<0.001 vs control. (h) Effects of GLP-1(9–36) on glucagon secretion in islets from cadaveric healthy donors. Each data point represents a unique group of 12 islets isolated from 13 healthy donors (black bars and grey symbols) and 3 donors with type 2 diabetes (red bars and symbols). Glucagon secretion has been normalised to that at 1 mmol/l glucose (1=7.01±0.91 and 2.41±0.62 pg islet−1 h−1 from experiments carried out on islets from donors without and with type 2 diabetes, respectively). ***p<0.001 vs no GLP-1(9–36) in islets from healthy donors (one-way ANOVA with Dunnett’s post hoc test)CC BY · PubMed Central
Fig. 9 Effects of GLP-1(9–36) on plasma glucose and glucagon secretion during insulin-induced hypoglycaemia. (a) Plasma glucagon measured in mice with (red squares) or without (black squares) injection of GLP-1(9–36) (100 µg/kg body weight; at t=−15 min). GLP-1(9–36) was injected intraperitoneally and samples were taken at indicated times. At t=0 min, insulin (0.75 U/kg i.p.) was injected. Data are mean values ±SEM of 13 or 14 mice. (b) Dot plots of glucagon AUCs measured during 45 min following injection of insulin at t=0 min and later in (a) in the absence (black triangles) or presence (red triangles) of exogenous GLP-1(9–36). *p<0.05 vs control by Student’s t test. (c) Changes in plasma glucagon during insulin-induced hypoglycaemia (0.75 U/kg body weight i.p.) under control conditions (black squares/lines) and in mice pretreated with REMD2.59 with (grey squares/lines) or without (red squares/lines) pre-injection of GLP-1(9–36) (100 µg/kg body weight). (d) Dot plots of the AUCs of data in (c) under the indicated conditions. *p=0.05 and †p<0.05 vs no REMD2.59 with/without GLP-1(9–36) control. (e) Relationship between plasma glucose and glucagon in vivo measured in (d). Data in REMD2.59-treated mice with/without GLP-1(9–36) were pooled. The black and red lines represent linear fits to the data points under control conditions (r=−0.77) and after pretreatment with REMD2.59 (r=−0.59; p<0.011 vs no REMD2.59). (f) Whole-pancreas glucagon content in control mice and mice pretreated with REMD2.59. **p<0.01 (Student’s t test)
Fig. 9 Effects of GLP-1(9–36) on plasma glucose and glucagon secretion during insulin-induced hypoglycaemia. (a) Plasma glucagon measured in mice with (red squares) or without (black squares) injection of GLP-1(9–36) (100 µg/kg body weight; at t=−15 min). GLP-1(9–36) was injected intraperitoneally and samples were taken at indicated times. At t=0 min, insulin (0.75 U/kg i.p.) was injected. Data are mean values ±SEM of 13 or 14 mice. (b) Dot plots of glucagon AUCs measured during 45 min following injection of insulin at t=0 min and later in (a) in the absence (black triangles) or presence (red triangles) of exogenous GLP-1(9–36). *p<0.05 vs control by Student’s t test. (c) Changes in plasma glucagon during insulin-induced hypoglycaemia (0.75 U/kg body weight i.p.) under control conditions (black squares/lines) and in mice pretreated with REMD2.59 with (grey squares/lines) or without (red squares/lines) pre-injection of GLP-1(9–36) (100 µg/kg body weight). (d) Dot plots of the AUCs of data in (c) under the indicated conditions. *p=0.05 and †p<0.05 vs no REMD2.59 with/without GLP-1(9–36) control. (e) Relationship between plasma glucose and glucagon in vivo measured in (d). Data in REMD2.59-treated mice with/without GLP-1(9–36) were pooled. The black and red lines represent linear fits to the data points under control conditions (r=−0.77) and after pretreatment with REMD2.59 (r=−0.59; p<0.011 vs no REMD2.59). (f) Whole-pancreas glucagon content in control mice and mice pretreated with REMD2.59. **p<0.01 (Student’s t test)CC BY · PubMed Central
Fig. 10 Regulation of glucagon secretion by physiological concentrations of GLP-1(7–36) and (9–36) via paracrine and intrinsic alpha cell mechanisms. (a) GLP-1(7–36) inhibits glucagon secretion by dual effects (indicated by 1 and 2). (1) Activation of GLP-1Rs in beta and delta cells stimulates the release of paracrine inhibitors of glucagon secretion. This mechanism is suppressed by pharmacological [using exendin(9–39)] or genetic inactivation of the GLP-1R. (2) GLP-1(9–36), generated by (DPP-4-mediated) degradation of GLP-1(7–36), results in activation of an inhibitory GTP-binding protein (Gi/o), culminating (via undocking of secretory granules [SG] below the plasma membrane) in suppression of glucagon secretion. This mechanism is not affected by genetic/pharmacological inactivation of the GLP-1R but is sensitive to pertussis toxin. It is not activated by exendin-4, which is more resistant to DPP-4-induced degradation than GLP-1(7–36). GLP-1(7–36) will activate both (1) and (2) but exogenous GLP-1(9–36) will only activate (2). (b) Concentration-dependent inhibition of glucagon secretion by GLP-1(9–36). Because of high circulating GLP-1(9–36) levels, administration of high exogenous GLP-1(9–36) will only have a marginal additional glucagonostatic effect (red arrow). GRAs lead to a large increase in circulating glucagon by reversing the glucagonostatic effects of endogenous GLP-1(9–36) (black arrow)
Fig. 10 Regulation of glucagon secretion by physiological concentrations of GLP-1(7–36) and (9–36) via paracrine and intrinsic alpha cell mechanisms. (a) GLP-1(7–36) inhibits glucagon secretion by dual effects (indicated by 1 and 2). (1) Activation of GLP-1Rs in beta and delta cells stimulates the release of paracrine inhibitors of glucagon secretion. This mechanism is suppressed by pharmacological [using exendin(9–39)] or genetic inactivation of the GLP-1R. (2) GLP-1(9–36), generated by (DPP-4-mediated) degradation of GLP-1(7–36), results in activation of an inhibitory GTP-binding protein (Gi/o), culminating (via undocking of secretory granules [SG] below the plasma membrane) in suppression of glucagon secretion. This mechanism is not affected by genetic/pharmacological inactivation of the GLP-1R but is sensitive to pertussis toxin. It is not activated by exendin-4, which is more resistant to DPP-4-induced degradation than GLP-1(7–36). GLP-1(7–36) will activate both (1) and (2) but exogenous GLP-1(9–36) will only activate (2). (b) Concentration-dependent inhibition of glucagon secretion by GLP-1(9–36). Because of high circulating GLP-1(9–36) levels, administration of high exogenous GLP-1(9–36) will only have a marginal additional glucagonostatic effect (red arrow). GRAs lead to a large increase in circulating glucagon by reversing the glucagonostatic effects of endogenous GLP-1(9–36) (black arrow)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

3 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 67 references

Cited by

See all 31

Metadata

Authors
Gandasi, N. R., Gao, R., Kothegala, L., Pearce, A., Santos, C., Acreman, S., Basco, D., Benrick, A., Chibalina, M. V., Clark, A., Guida, C., Harris, M., Johnson, P. R. V., Knudsen, J. G., Ma, J., Miranda, C., Shigeto, M., Tarasov, A. I., Yeung, H. Y., Thorens, B., Asterholm, I. W., Zhang, Q., Ramracheya, R., Ladds, G., & Rorsman, P.
Affiliations
  • Indian Institute of Science Bangalore (IN)
  • Churchill Hospital (GB)
  • University of Gothenburg (SE)
  • University of Cambridge (GB)
  • University of Lausanne (CH)
  • University of Copenhagen (DK)
  • University of Ulster (GB)
Corresponding author
Rorsman, Patrik
Venue
Diabetologia
Published
2023-12-21
Volume
67
Issue
3
Pages
528-546
ISSN
  • 0012-186X (ISSN-L)
  • 1432-0428
OpenAlex
W4390061924
Cited by
31
References
67
Citations by year
2026: 7 · 2025: 10 · 2024: 14
FWCI
8.28
Type
journal article
Language
en
Open access
Licence
Locations
  • Diabetologia (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
  • Ulster University Research Portal (Ulster University) (acceptedVersion, other-oa)
  • SERVAL (Université de Lausanne) (acceptedVersion, other-oa)
  • IRIS (submittedVersion, cc-by)
  • Apollo (University of Cambridge) (submittedVersion, cc-by)
  • Apollo (cc-by)
Funders
  • Vetenskapsrådet (2013-7107, 2020-01463, 2020-02485)
  • University of Gothenburg
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
Keywords
GLP-1(7-36), glucagon secretion, pancreatic islets, alpha cells, type 2 diabetes, GLP-1 receptor, secretory granules, protein kinase A, glucagon receptor, beta-adrenergic stimulation, calcium signaling
MeSH terms
Diabetes Mellitus, Type 2, Glucagon, Humans, Hypoglycemia, Insulin, Islets of Langerhans, Peptide Fragments, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: GLP-1 metabolite GLP-1(9–36) is a systemic inhibitor of mouse and human pancreatic islet glucagon secretion. https://app.cochat.ai/papers/10.1007/s00125-023-06060-w
The paper
Gandasi, N. R., Gao, R., Kothegala, L., Pearce, A., Santos, C., Acreman, S., Basco, D., Benrick, A., Chibalina, M. V., Clark, A., Guida, C., Harris, M., Johnson, P. R. V., Knudsen, J. G., Ma, J., Miranda, C., Shigeto, M., Tarasov, A. I., Yeung, H. Y., . . . Rorsman, P. (2024). GLP-1 metabolite GLP-1(9–36) is a systemic inhibitor of mouse and human pancreatic islet glucagon secretion. Diabetologia. https://doi.org/10.1007/s00125-023-06060-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.